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The serine/threonine phosphatase calcineurin (Cn)
targets the nuclear factors of activated T cells
(NFATs) that activate cytokine genes. Calcium influx
activates Cn to dephosphorylate multiple serine
residues within the 200 residue NFAT regulatory
domain, which triggers joint nuclear translocation
of NFAT and Cn. The dephosphorylation process
relies on the interaction between Cn and the
conservedmotifs PxIxIT and LxVP, which are located
N- and C-terminal to the phosphorylation sites in
NFAT’s regulatory domain. Here, we show that an
NFATc1-derived 15-residue peptide segment con-
taining the conserved LxVPmotif binds to an epitope
on Cn’s catalytic domain (CnA), which overlaps with
the previously established PxIxIT binding site on
CnA and is distant to the regulatory domain (CnB).
Both NFAT motifs partially compete for binding but
do not fully displace each other on the CnA epitope,
revealing that both segments bind simultaneously to
the same epitope on the catalytic domain.
INTRODUCTION
The nuclear factors of activated T cells (NFATs) are transcription
factors that regulate numerous genes upon T cell activation
(Hogan et al., 2003; Rao et al., 1997; Serfling et al., 2000). They
upregulate cytokines required for T cell proliferation and stimu-
late cell growth and differentiation during the T cell response
(Kiani et al., 2000). Four of the five known NFAT proteins are
part of the T cell response mechanism (Macian, 2005), but
NFAT proteins also take part in different regulatory mechanisms
of other cells (Crabtree and Olson, 2002; Graef et al., 2001;
Hogan et al., 2003; Kao et al., 2009). The C-terminal half of
the 930-residue NFAT contains two domains involved in binding
DNA and AP-1 and has been characterized structurally (Chen
et al., 1998; Jin et al., 2003; Wolfe et al., 1997; Zhou et al.,1016 Structure 22, 1016–1027, July 8, 2014 ª2014 Elsevier Ltd All rig1998). The N-terminal half known as the NFAT homology region
(NHR) contains a transactivation domain (TAD) and a regulatory
domain (Figure 1A). The regulatory domain of approximately 200
residues contains a nuclear localization region (NLS), 3 serine-
proline (SP)-rich repeats, and 2 serine-rich regions (SRR). Phos-
phorylation status of these segments controls NFAT nuclear
import and export by yet unknown mechanisms. In resting
T cells, the regulatory domain is heavily phosphorylated, pre-
venting NFAT from entering the nucleus. Four kinases are known
to phosphorylate NFAT: casein kinase 1 (CK1), glycogen syn-
thase kinase 3 (GSK3), protein kinase A (PKA), and the dual
specificity tyrosine phosphorylation kinase (DYRK) (Arron et al.,
2006; Gwack et al., 2006; Okamura et al., 2000; Okamura
et al., 2004). Rising Ca2+ levels, such as caused by mitogens,
activate the calcium-dependent phosphatase calcineurin (Cn),
a heterodimeric protein consisting of a catalytic domain (CnA)
and a calmodulin-like regulatory domain (CnB). CnB constitu-
tively binds to the C-terminal side of CnA to form the heterodimer
(hereafter we call the heterodimeric CnA/CnB complex CnAB).
Following activation, Cn dephosphorylates NFAT and initiates
joint nuclear translocation of both NFAT and Cn (Shibasaki
et al., 1996). The nuclear entry event also involves other proteins,
such as importin-b and tubulin-a (Ishiguro et al., 2011). In the
nucleus, NFAT assembles with other transcription factors and
coactivators to initiate the immune response (Flanagan et al.,
1991; Jain et al., 1992; Wu et al., 2007).
Two distinct Cn-binding segments have been identified in the
NHR of all NFAT isoforms involved in T cell response. They
contain the conserved PxIxIT and LxVP motifs and are labeled
CN-1 and CN-2 in Figure 1A. The NHR was found unstructured,
both in its active and inactive states (Park et al., 2000). The PxIxIT
motif was discovered first and is highly conserved among NFAT
isoforms (Aramburu et al., 1998; Zhu et al., 1998). Peptides con-
taining the endogenous PxIxIT sequence (PRIEIT in NFATc1/c2)
bind calcineurin with low to midmicromolar affinities (Aramburu
et al., 1998). The nonconserved amino acids (x) in positions 2
and 4 modulate the binding affinities, and these residues are
thought to cause fine-tuning of this interaction under different
physiological conditions (Li et al., 2007). Affinity-driven selection
of peptide inhibitors resulted in an optimized peptide that binds
Cn with a 200 nM dissociation constant (KD). Residues inhts reserved
Figure 1. Location of Functional Segments
in NFAT’s Homology Region
(A) Sequences of Cn-binding regions. Residues
conserved throughout the different human NFAT
isoforms are highlighted in yellow. The following
abbreviations are used to represent the functional
segments: TAD, transactivation domain; CN-1 and
CN-2, the conserved binding motifs of Cn PxIxIT
and LxVP; SRR-1 and SRR-2, serine-rich regions;
SP1, SP2, and SP3, serine-proline rich repetition
segments; NLS, nuclear localization sequence.
(B) NFAT-conserved motifs, PxIxIT and LxVP,
primary amino acid sequences throughout the
different human NFAT isoforms.
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sequence (Aramburu et al., 1999; Li et al., 2011). Structures of
CnAB and CnA in complex with a 14-mer NFAT peptide contain-
ing the PVIVIT sequence have been determined with X-ray crys-
tallography (Li et al., 2007) and nuclear magnetic resonance
(NMR) spectroscopy (Takeuchi et al., 2007).
More recently, a second Cn-binding segment was discovered
that contains the conserved LxVP sequence. Located C-terminal
to NFAT’s regulatory domain, it binds Cn with similar affinity as
the PxIxIT segment. Furthermore, it was observed that blocking
the interaction of Cn with the PxIxIT motif alone does not prevent
NFAT nuclear translocation. Thus, it was concluded that the
interaction of Cn with the LxVP motif is necessary for an efficient
dephosphorylation process (Liu et al., 1999; Park et al., 2000).
Because of its role in T cell activation, Cn has been targeted for
development of immune-suppressive drugs. The most success-
ful Cn inhibitors discovered so far, cyclosporin A (CsA) and tacro-
limus (FK506), block Cn’s phosphatase activity by obscuring its
catalytic site. They are presented as stable dimeric complexes
with the intracellular proteins cyclophilin or FKBP12, respectively
(Griffith et al., 1995; Huai et al., 2002; Kissinger et al., 1995). More
recently, significant effort has been made to specifically inhibit
the Cn-NFAT complex formation without blocking Cn’s catalytic
activity, thus leading to a more selective agent by enabling Cn to
continue with its other roles (Roehrl et al., 2004a, 2004c). For that
purpose, the inhibition of the PxIxIT site was extensively pur-
sued, whereas less effort was directed toward blocking the
LxVP interaction due to lack of structural data (Lee and Park,
2006; Zhou et al., 2011).
Recently, it was suggested based on mutations and docking
calculations that a peptide containing the NFAT-LxVP motif
binds a region near the interface of CnA and CnB (Rodrı´guez
et al., 2009). An LxVP binding site was also suggested based
on a cocrystal structure of CnAB with the viral inhibitor protein
A238L, which binds the CnA/B interface with an FLCVK motif
(Grigoriu et al., 2013). Besides the P/K replacement, the LxVK
segment also lacks the flanking residues found in NFAT’s LxVP
segments, some of which were recently shown to be important
for its activity (Rodrı´guez et al., 2009).
Here, we present evidence that a 15-mer peptide from
NFATc1 containing the conserved LxVP sequence binds to aStructure 22, 1016–1027, July 8, 2014 ªCnA region overlapping with the PxIxIT-
binding epitope. NMR competition ex-
periments show that the LxVP and PxIxITpeptides partially displace each other at equimolar concentra-
tions, suggesting that they bind simultaneously at overlapping
binding epitopes, where they interact with each other. This con-
tradicts previous proposals that the two motifs bind at two
distant Cn sites. Our conclusion is supported by biophysical
and atomic resolution data obtained through NMR spectroscopy
and fluorescence polarization (FP) measurements. Our findings
suggest that it should be possible to inhibit the Cn/NFAT interac-
tion with a single inhibitory molecule, which would have been
difficult with two distant binding sites.
RESULTS
To characterize calcineurin binding of NFAT’s homology domain,
we selected two NFAT peptides containing the PxIxIT or LxVP
motifs, respectively (Figure 1). The locations of the motifs in the
NFAT homology region (NHR) are depicted in Figure 1A and
are labeled CN-1 and CN-2, respectively. Figure 1B shows
sequence alignments for both segments of the four T-cell-
related human NFAT isoforms. Note that there is a WxK motif
C-terminal to the LxVP sequence, which motivated us to use
the longer 15-residue segment of NFATc1 for our binding
studies. Indeed, theWxKmotif seems to be important for activity
of the LxVP motif (see below), which is consistent with previous
studies (Rodrı´guez et al., 2009).
The CnA construct used here is identical to that described in
previous structural and functional studies (Kang et al., 2005;
Roehrl et al., 2004c). It comprises residues 2–347 of the native
human CnA with Y341S, L343A, and M347D substitutions that
increase protein solubility for NMR experiments. These mutated
residues are located >20 A˚ away from the active site and do not
affect the enzymatic activity of CnA. The heterodimeric CnAB
used here contains the native sequence.
The NFATc1-Derived LxVP Peptide Interacts with CnA
To determine whether the NFAT-LxVP peptide binds CnA alone
or requires the entire CnAB heterodimer, we compared NMR
spectra of the 15N-labeled peptide alone and upon addition
of either CnA or CnAB. Figure 2A shows a heteronuclear
single-quantum coherence (HSQC) spectrum of unbound 15N-
labeled NFAT-LxVP peptide, and Figure 2B is an expansion2014 Elsevier Ltd All rights reserved 1017
Figure 2. The NFAT-LxVP Peptide Interacts with CnA of Cn
(A) 2D 1H-15N HSQC spectrum of free 62 mM 15N-labeled NFAT-LxVP peptide.
The signal marked with an asterisk is an extra residue of the C-terminal His tag
and is not relevant in this context.
(B) Inset of Figure 2A, which contains the relevant peaks and serves as a
reference for the panels below.
(C) 2D 1H-15N HSQC spectra of 15N-NFAT-LxVP peptide in the presence of
nonlabeled CnA (left) and nonlabeled CnAB (right), which was acquired at an
LxVP:Cnmolar ratio of 1:1.2. In all 2D spectra, ten contour plot levels are drawn
starting at 1.53 105 and increasing by a factor of 1.40 for each additional level.
Peak heights for complexes of 15N-NFAT-LxVP peptides with CnA and CnAB
are documented in the bar graphs of Figures 4 and S2.
(D) Semilogarithmic plots of fluorescence polarization experiments for deter-
mining KD of NFAT-LAVP (red), NFAT-PRIEIT (blue), and PVIVIT (black) pep-
tides. Each FITC-labeled peptide (30 nM) was incubated with increasing
amounts of the GST-CnA (left) and CnAB (right). The binding affinity was
determined using the software GraphPad Prism6 by fitting the data to a single-
site binding model. Note that a dimeric GST fusion construct was used for
CnA to increase the molecular mass of the complex and increase the fluo-
rescence anisotropic difference between bound and free peptide. Thus, the
bound FP of GST-CnA is larger than that of CnAB.
Table 1. Equilibrium Dissociation Constants for the NFAT-LxVP
and PxIxIT Peptide Interactions with CnA and CnAB
CnA CnAB
LxVP KD = 3.1 ± 0.44 mM KD = 3.2 ± 0.70 mM
PRIEIT KD = 2.5 ± 0.76 mM KD = 4.2 ± 1.1 mM
PVIVIT KD = 0.53 ± 0.11 mM KD = 0.51 ± 0.13 mM
The equilibrium dissociation constants were measured using the fluores-
cence polarization assay from Figure 2D.
Structure
NFAT’s PxIxIT and LxVP Bind Calcineurin Jointlywith all signals, except the C-terminal histidine. Next, we added
either nonlabeled CnA (Figure 2C, left) or nonlabeled CnAB
(Figure 2C, right) to 15N-labeled NFAT-LxVP. Very similar spec-
tral changes are observed: the same peaks are broadened, lead-1018 Structure 22, 1016–1027, July 8, 2014 ª2014 Elsevier Ltd All riging to reduced peak heights when adding either the CnA or the
CnAB. Most affected are L387 and A388 of the LAVP motif and
Y394 and W396 of the C-terminal flanking sequence (Figure 1).
Broadening of peptide peaks upon binding to larger proteins is
typically seen for residues contacting the larger molecule due
to immobilization and slower tumbling and/or exchange between
slightly different bound conformations.
Figure 2C shows that the same set of signals of the LxVP pep-
tide are broadened upon binding to either CnA or CnAB. This
indicates a similar bindingmode to both CnA and CnAB and sug-
gests LxVP’s binding to the common moiety CnA. Some resi-
dues exhibit slightly different broadening behavior when titrating
CnA or CnAB. For example, the intensity reduction of the signal
originating fromQ391 ismore pronouncedwhen bound toCnAB.
This may be the result of exchange between slightly different
bound conformations in the presence of the heterodimer CnAB
or the higher molecular weight of the CnAB complex with NFAT-
LxVP. It may also be due to a more anisotropic tumbling of the
elongated CnAB compared to the more spherical CnA.
Next, we asked whether the presence of CnB causes tighter
binding of the LxVP peptide. Using a FP assay (Roehrl et al.,
2004b, 2004c), we measured affinities of fluorescein-tagged
NFAT-LxVP peptide to CnA (glutathione S-transferase [GST]-
tagged; GST-CnA) or CnAB. Figure 2D shows FP titrations of
GST-CnA (left) and CnAB (right) to samples of NFAT-LxVP
(red), NFAT-PRIEIT (blue), and the affinity-enhanced PVIVIT
(black line) peptides. Fitting with a single-site binding model
yields the KD values in Table 1, which are consistent with the
KD of 2.5 mMmeasured previously with isothermal titration calo-
rimetry (ITC) for the LxVP peptide (Park et al., 2000). The struc-
ture of the complex of the affinity-optimized PVIVIT peptide
with calcineurin and the PVIVIT affinity to CnA are well estab-
lished and serve as positive controls. Indeed, the obtained KD
suggests that our experimental conditions are congruent with
previously reported data, indicating a dissociation constant of
about 0.5 mM between the PVIVIT peptide and Cn (Roehrl
et al., 2004a, 2004c). These results show that the NFAT-LxVP
peptide binds to either CnA alone or CnAB with similar affinity,
and the presence of CnB does not enhance binding of the
LxVP peptide.
To verify these results with an orthogonal method, we mea-
sured direct binding of His-GB1-NFAT-PRIEIT and His-GB1-
NFAT-LxVP to GST-CnA using BLItz technology, which yields
association and dissociation rates and equilibrium dissociation
constants. We found that the NFAT-PRIEIT peptide has 10-fold
faster association and dissociation rates than does NFAT-
LxVP. However, the KD values measured with BLitz are almost
identical for both peptides at 0.64 and 0.46 mM, respectivelyhts reserved
Figure 3. Characterization of the CnA:
NFAT-LxVP Binding Epitope by NMR Spec-
troscopy
(A) 2D 1H-15N TROSY-HSQC NMR spectrum of
[U-2H15N] CnA. The spectrum was acquired on a
600 MHz spectrometer with 2,048 (10 ppm)3 128
(30 ppm) complex points (SW) in the direct and
indirect dimensions, respectively.
(B) Insets of representative regions from the series
of the 2D HSQC TROSY-NMR spectra acquired
during the titration of unlabeled NFAT-LxVP pep-
tide (residues 384–400 of NFATc1) to [U-2H15N]
CnA (residues 2–347). The spectra show CnA
peaks in the absence of NFAT-LxVP (red) and in
the presence of 1:0.25 (cyan), 1:1 (green), 1:3
(purple), and 1:5.5 (yellow) CnA:NFAT-LxVP molar
ratios as depicted in the color legend on top of the
panels. A complete record of the chemical shift
perturbations for the assigned signals of CnA
together with paramagnetic relaxation enhance-
ment experiments are shown in Figure S1.
(C) Solution structure of the complex of CnA (gray)
with a 15-residue PVIVIT peptide (Takeuchi et al.,
2007). The active-site metals (Zn/Fe) are shown
with solid spheres.
(D) Residues of CnA that exhibit chemical shift
changes upon binding the PVIVIT peptide.
(E) Residues of CnA that exhibit chemical shift
changes upon binding to the 15-residues NFAT-
LxVP peptide. Large and small spheres represent
chemical shift differences larger than 0.1 and
0.05 ppm, respectively.
Structure
NFAT’s PxIxIT and LxVP Bind Calcineurin Jointly(Figure S3 and Table S1 available online). This is consistent with
previous reports (Liu et al., 1999; Park et al., 2000) and confirms
that the NFAT- PRIEIT and NFAT-LxVP peptides bind CnA with
equal affinities.
The NFAT-LxVP and PVIVIT Peptides Bind to
Overlapping Epitopes on CnA
Having established that NFAT-LxVP binds to CnA, we turned
to identify the exact binding epitope at a residue level using
NMR-chemical shift perturbation (CSP). We titrated nonlabeled
NFAT-LxVP peptide into an NMR sample of 15N, 2H-CnA. Fig-
ure 3A shows a 2D 1H-15N-correlated TROSY-HSQC spectrum
of the 40 kDa CnA alone. We then titrated the nonlabeled
NFAT-LxVP peptide (Figure 1B) and followed the CSP of CnA
in 2D TROSY-HSQC spectra. Figure 3B shows three insets
from different regions of the CnA HSQC spectra (boxed in
Figure 3A), wherein both types of shifted and nonshifted residuesStructure 22, 1016–1027, July 8, 2014 ªcan be observed. The shifted residues
showed fast-to-intermediate exchange,
which is typical for low micromolar
interactions.
Because the bound structure of the
PVIVIT peptide is known, we compared
the CnA chemical shift changes upon
binding of the PVIVIT (Figure S1A) and
NFAT-LxVP peptides (Figure S1B). In
addition to the chemical shift changes
documented in Figures S1A and S1B,some residues experience severe line broadening during the
addition of the NFAT-LxVP peptide as they appear to reach the
limit of intermediate exchange. Residues with the largest
changes are listed in the supplement (Figure S1). This pattern
is similar, but not identical, to that of the PVIVIT peptide.
Note that we have incomplete assignments for the CnA
construct used here. The residues around the paramagnetic
center of the protein are not assigned due to paramagnetic
line broadening. Moreover, because the protein was expressed
in D2O, we lack the assignments for residues located in the
hydrophobic core that did not back exchange amides 2H to
1H. Yet, most surface residues away from the paramagnetic
center are assigned, and the identification of the binding
epitope is complete. Moreover, the assignments of the binding
epitope have been validated by structure determination of the
Cn/VIVIT peptide complex (Li et al., 2007; Takeuchi et al.,
2007).2014 Elsevier Ltd All rights reserved 1019
Figure 4. PVIVIT Competes out NFAT-LxVP
from CnAB
(A–C) 2D 1H-15N HSQC spectra of the following:
(A) 62 mM 15N-labeled NFAT-LxVP alone. (B) 15N-
labeled NFAT-LxVP in a complex with CnAB in
1:1.2 molar ratio. Peaks of the residues contacting
CnAB are strongly reduced, and some are also
slightly shifted. (C) Addition of unlabeled His6-
GB1-PVIVIT (left) in a 1:1.2:5 molar ratio restores
intensity of some peaks (L387, A388, and V389;
the LxV of LxVP motif), but not of others (Y294,
W396, A397, and K398; the WxK motif). Addition
of unlabeled His6-GB1 as a control (right) does not
restore the intensity changes. The spectra were
acquired on a 600 MHz spectrometer with 2,048
(10 ppm) 3 128 (30 ppm) complex points (spec-
trum width [SW]) in the direct and indirect di-
mensions, respectively. In order to document the
intensity changes, cross-sections are drawn
through the peak of L387 in all four panels.
(D) Bar graph indicating the relative peak intensity
of NFAT-LxVP peaks corresponding to each of the
four spectra in (A)–(C) with peak colors similar to
the representative bars. The error bars indicate the
noise levels in the respective spectra as extracted
from SPARKY using median of 10,000 calculated
points.
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direct and indirect interactions, such as allosteric effects. To
detect only direct spatial-related interaction, we used paramag-
netic relaxation enhancement (PRE). We attached the methane-
thiosulfonate (MTSL) spin label to the thiol of mutated Q385C in
the second position of the LxVP peptide. We compared the in-
tensities of CnA backbone NH cross-peaks when bound to
NFAT-LxVP-MTSL before and after reducing the spin label with
ascorbic acid (Figure S1C). Residues most affected coincide
with the known PVIVIT binding region on CnA, confirming that
both peptides bind to a common epitope.
Tovisualize theNMRmappingof thepeptidebinding,Figure3C
shows a cartoon of CnA in complex with the PVIVIT peptide
(orange colored) (Takeuchi et al., 2007). The CnA residues with
the largest chemical shift changes upon binding the PVIVIT and
NFAT-LxVP peptides are indicated with red and blue spheres in
Figures 3D and 3E, respectively. As can be seen, the similarity
of the sets of Cn residues that interact with PVIVIT or NFAT-LxVP1020 Structure 22, 1016–1027, July 8, 2014 ª2014 Elsevier Ltd All rights reservedreveals that the two peptides bind
approximately the same epitope on CnA.
However, the NFAT-LxVP peptide affects
more strongly a helical region above the
PVIVIT binding site (top left of Figure 3E).
Thus, the residues that are perturbed
upon binding by both peptides on CnA
are overlapped but are not identical.
The PxIxIT and LxVP Motifs
Compete for Binding to CnAB,
but Only Partially
Having shown that both NFAT-LxVP and
PVIVIT-containing peptides bind to an
overlapping surface of CnA, we askedwhether the two motifs bind competitively. First, we recorded
1H-15N-correlated spectra of 15N-labeled NFAT-LxVP alone (Fig-
ure 4A) and following the addition of unlabeled CnAB (Figure 4B)
similar to Figure 2C. In a second step, we added the unlabeled
PVIVIT peptide to the complex to see whether it competes out
the 15N-labeled NFAT-LxVP peptide. Four peaks that display
strongest intensity changes (L387, A388, V389, and Y394) are
labeled in the spectra. In order to document the size of the inten-
sity losses, cross-sections are drawn for L387 as a representa-
tive case. Addition of unlabeled GB1-PVIVIT to this sample
(Figure 4C, left panel) leads to the reappearance of some of
the affected signals (L387, A388, and V389; the residues of the
LxVP segment), whereas others remain suppressed (Y394). As
a negative control, addition of GB1 alone does not produce
this effect (Figure 4C, right panel). In addition, we verified that
the GB1 protein did not interact with the NFAT-LxVP segment
by recording 2D HSQC spectra of 15N-labeled GB1 with
and without the NFAT-LxVP peptide (Figure S4). A complete
Figure 5. GB1-LxVP Partially Displaces
15N-PxIxIT from CnAB
(A–C) 2D 1H-15N HSQC spectra of the following:
(A) 75 mM 15N-labeled NFAT-PRIEIT alone,
(B) 15N-labeled NFAT-PRIEIT in a complex with
heterodimer CnAB in 1:1.2 molar ratio, (C) and
addition of GB1-LxVP-His6 (C-left) and unlabeled
His6-GB1 (C-right) in a 1:1.2:5 molar ratio. The
spectra were acquired on a 600 MHz spectrom-
eter with 2,048 (10 ppm) 3 128 (30 ppm) complex
points (SW) in the direct and indirect dimensions,
respectively. In order to document the intensity
changes, cross-sections are drawn through the
peaks of T21 and E19 in all four panels.
(D) Bar graph reporting the intensities of NFAT-
PRIEIT peaks corresponding to each of the
different spectra from (A)–(C) with peak colors
similar to the representative bars. The error bars
indicate the noise levels in the respective spectra
as extracted from SPARKY using median of
10,000 calculated points.
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bar graph of Figure 4D. Detailed inspection of Figure 4D sug-
gests that the segment D384 to Q391 from the NFAT-LxVP pep-
tide is tightly bound when adding CnAB, but it is also displaced
again when adding GB1-PVIVIT. In contrast, the segment Y394
to L399 clearly binds CnAB but is not displaced by GB1-PVIVIT.
Interestingly, the latter segment contains the conserved
WxK sequence, which thus seems to be important for the
NFAT-LxVP peptide binding and responsible for the fact that
the PVIVIT, or more generally the PxIxIT, peptides cannot fully
displace the NFAT-LxVP peptide. Based on the KD listed in Table
1, the addition of 75 mM CnAB to the sample of 62 mM NFAT-
LxVP causes 90% of the peptide to be bound to CnAB. This
agrees with the peak intensity changes for key residues L387-
V389. The addition of four molar excess of the PVIVIT peptide
used for this experiment should have resulted in complete
displacement. Yet, some of the NFAT-LxVP residues remain
bound. These observations suggest that both NFAT segments,Structure 22, 1016–1027, July 8, 2014 ªthe NFAT-LxVP and the PVIVIT, only
partially compete for the same binding
site and that the PVIVIT does not fully
displace the NFAT-LxVP peptide. In addi-
tion, spectra of CnAB-bound 15N-labeled
NFAT-LxVP with and without unlabeled
PVIVIT peptide are not identical. Thus,
both peptides must bind simultaneously
on the surface of CnAB. In order to test
whether the same effects occur if only
using CnA, we performed similar experi-
ments with only CnA and obtained equiv-
alent results as shown in Figure S2.
In a complementary experiment, we
checked whether the peptide containing
the LxVP motif can displace PRIEIT. We
added nonlabeled CnAB to a sample
of 15N-labeled NFAT-PRIEIT peptide.
Similar to the previous experiment, the
competitor LxVP peptide was expressedwith a GB1-tag, which was also used alone as negative control.
Figure 5A shows the 2D HSQC spectrum of the free 15N- NFAT-
PRIEIT peptide (top panel). Addition of CnAB causes a subset
of peaks to shift or disappear (middle panel). The cumulative
loss of peak intensity indicates the complex formation of the
PRIEIT peptide with CnAB. We then added the nonlabeled
NFAT-LxVP peptide to examine whether it also partially com-
petes out the PRIEIT (lower left panel). Unlike the previous exper-
iment depicted in Figure 4, where the tighter binder GB1-PVIVIT
was used, the two peptides examined here now have endoge-
nous sequences and are with comparable affinities toward Cn
(Table 1). Yet, when competing with a 4-fold excess of GB1-
LxVP on exactly the same binding epitope, a full displacement
of 15N-NFAT-PRIEIT should occur according to the law of
mass action. However, only a subset of the attenuated peaks re-
appears upon addition of the GB1-LxVP peptide. This confirms
partial, but not full, competition between the NFAT-LxVP and
NFAT-PRIEIT peptides. Two representative peaks are labeled2014 Elsevier Ltd All rights reserved 1021
Figure 6. Monitoring the Displacement of
NFAT-PRIEIT and NFAT-LxVP Peptides
Using an FP Assay
(A) Displacement of the FITC-labeled NFAT-LxVP
by the NFAT-PRIEIT peptide. Increasing concen-
trations of the NFAT-PRIEIT peptide were titrated
into a mixture of 30 nM FITC-NFAT-LxVP peptide
and 1.2 mM GST-CnA (left) and 3.0 mM CnAB
(right).
(B) Displacement of the FITC-labeled PRIEIT by
the LxVP peptide. Increasing concentrations of
the LxVP peptide were titrated into a mixture
of 30 nM FITC-PRIEIT peptide with 1.2 mM GST-
CnA (left) and 3.0 mM CnAB (right). Note that
the NFAT-derived PxIxIT and LxVP peptides will
always be presented at equimolar concentrations
as part of the same NFAT molecule. The experi-
ment shown here documents that the two NFAT
segments target the same epitope on CnA but
do not displace each other as part of full-length
NFAT.
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PRIEIT motif suggests that its displacement from the binding
epitope on Cn occurred following the addition of the NFAT-LxVP
peptide. Thus, the data provide additional support that the
PRIEIT and LxVP peptides bind to an overlapping region on
Cn. The histogram in Figure 5B details the relative intensities of
all NFAT-PRIEIT residues in each mode: free (black bars), bound
to Cn (red bars) after the addition of GB1-LxVP (blue bars), and
after the addition of GB1 as a negative control (green bars). It
can be seen that the residues in the core of the binding motif
exhibit the most pronounced intensity decrease upon CnAB
binding as well as intensity recovery after LxVP addition. How-
ever, the observation that some residues do not fully recover
after LxVP addition indicates simultaneous binding.
FP Experiments Confirm Competitive Binding of the
PxIxIT and LxVP Peptides to CnA and CnAB
To further validate the competitive binding of the two NFAT
derived peptides on both CnA and CnAB, we used a FP
displacement assay. In Figure 6A, we labeled the NFAT-LxVP
peptide with a fluorescein isothiocyanate (FITC) tag at its C ter-
minus and incubated a 30 nM solution of the peptide with
1.2 mM of GST-CnA (left panel) or 3.0 mM heterodimer CnAB
(right panel). To displace the FITC-labeled NFAT-LxVP peptide,
we added increasing amounts of unlabeled NFAT-PRIEIT
peptide. In each panel, the red and blue lines represent the
constant amount of NFAT-LxVP peptide with and without the
corresponding protein and without NFAT-PRIEIT. The green
line represents the wells wherein increasing amounts of NFAT-
PRIEIT peptide were added. It can be seen that the FITC-labeled
30 nM NFAT-LxVP peptide can be fully displaced at very high
excess (1,000-fold) of the NFAT-PRIEIT peptide in the mid to
high micromolar range. Figure 6B exhibits the results of a com-
plementary experiment wherein 30 nM FITC-PRIEIT peptide is1022 Structure 22, 1016–1027, July 8, 2014 ª2014 Elsevier Ltd All rights reservedincubated with 1.2 mM GST-CnA (left
panel) or 3.0 mM of CnAB (right panel).
Increasing concentrations of NFAT-LxVP peptide displaces the NFAT-PRIEIT peptide from both pro-
teins. These data support the notion that both peptides bind to
adjacent or overlapping epitopes on CnA. Note that higher con-
centrations of CnAB (3.0 mM) were used compared to GST-CnA
(1.2 mM), whereas the concentration of the FITC-labeled peptide
was the same. Thus, more titrant peptide is needed to displace
the bound peptide, which shifts the FP displacement curves
for CnAB to the right compared to those for GST-CnA. The fact
that a large excess of one peptide is required to displace the
other directly indicates that the overlap in the epitopes contrib-
utes only a modest amount to the overall affinity.
The high excess of NFAT-PRIEIT or NFAT-LxVP peptide over
the other FITC-labeled peptide used here is different from the
NMR competition experiment (Figure 5). In the NMR experiment,
we used approximately equimolar amounts of both peptides at
high micromolar concentrations. In vivo, the PRIEIT and LxVP
segments will always be present at equimolar concentrations,
because they are on the same NFAT molecule. Thus, the NMR
competition experiments that showed simultaneous binding to
the overlapping epitopes approximate this situation better. This
is confirmed by the results of Figure 6. At the lowest titrant con-
centrations, we have equimolar concentrations, and the pep-
tides do not displace each other, which is consistent with the
equimolar NMR competition experiments described above.
The fact that the separate peptides containing either the LxVP
or the PxIxIT peptides can displace the other peptide at high
excess supports the finding that the two NFAT peptides
compete for the same binding site. The observation that
displacement occurs at high excess of one peptide over the
other indicates that the PxIxIT or LxVP peptides alone adapt
bound structures that are incompatible with the other peptide
binding. Only at approximately equal peptide concentrations a
trimeric complex is formed where both peptides bind to CnA
and interact with each other.
Structure
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NFAT-specific inhibition of Cn in T cells has been an objective for
obtaining safe immune-suppressing agents. Inhibitors broadly
blocking the phosphatase activity of calcineurin, such as cyclo-
sporin A or FK506, in complex with their cytoplasmic receptors
cyclophilin and FKBP12, respectively, have been tremendously
successful and are now routinely used to prevent rejection in
organ transplants. However, the complete inhibition of Cn’s
enzymatic activity also affects all other functions of Cn outside
the immune system and has severe side effects in the long-
term treatment of transplant patients. Thus, there is a need for
specific inhibitors for Cn’s activity against NFAT only and not
blocking its function in other contexts outside the immune sys-
tem (Mullard, 2012). Indeed, initial inhibitors have been found
already that prevent NFAT binding to Cn, its dephosphorylation,
nuclear translocation, and upregulation of cytokines but do not
inhibit its general phosphatase activity against other targets
(Roehrl et al., 2004a, 2004c). Given the importance of this bind-
ing event, it is imperative to achieve a better structural under-
standing of the calcineurin-NFAT interaction, which would
facilitate the search for novel NFAT-specific Cn inhibitors.
The discovery of two distinct Cn binding motifs, PxIxIT and
LxVP, seemed to make it unlikely that the homology domain of
NFAT could be displaced from Cn with a single molecule. This
is in contrast to a previous study in which single compounds
could inhibit NFAT dephosphorylation and nuclear translocation
(Roehrl et al., 2004a, 2004c). Thus, a more detailed investigation
of the interaction sites of the two binding peptides was desirable.
In this study, we embarked on defining the binding site of an
NFAT-derived peptide containing the LxVP motif of NFATc1 on
Cn. Using NMR spectroscopy, we discovered that the peptide
containing the conserved NFAT-LxVP motif binds to the same
CnA surface region as the high-affinity PVIVIT peptide. This
finding was unexpected and is inconsistent with recent sugges-
tions based on mutagenesis and modeling that locate the LxVP
binding at the CnA/B interface (Rodrı´guez et al., 2009). Our
findings are also contrary to the claim that the binding site of
an LxVK sequence of the viral A238L protein represents NFAT’s
LxVP binding (Grigoriu et al., 2013). Besides the P/K difference,
the viral protein also lacks the flanking sequences native to
NFATs, including the WxK motif (Figure 1) that anchors the pep-
tide onto CnA. Indeed, it has previously been shown that W/A
mutation in the WxK motif impaired the inhibition activity of the
mutated LxVP peptide (Rodrı´guez et al., 2009). Moreover, the
binding affinity of the NFAT-LxVP peptide to Cn is similar to
both the heterodimer CnAB and CnA alone (Table 1). This bind-
ing affinity also resembles that of the peptide containing the
PxIxIT motif, which is known to bind explicitly to CnA. The simi-
larity of the binding affinities indicates that the LxVP binding
event manifests equal importance as the PxIxIT interaction.
This is consistent with previous reports that peptides containing
the LxVP sequence of NFATc1 (1) disrupt the NFAT/Cn interac-
tion, (2) displace the PxIxIT peptide of NFATc2 from Cn, (3) pre-
vent NFAT dephosphorylation, and (4) inhibit NFAT nuclear
translocation (Martı´nez-Martı´nez et al., 2006).
The data presented here reveal that both peptides bind to epi-
topes on CnA that overlap but are not identical. The peptides
containing the LxVP and PxIxIT motifs bind simultaneouslyStructure 22, 1when presented at equimolar concentrations as shown in Fig-
ures 4, 5, and 6. Equimolar concentrations resemble the binding
event of the full-length NFAT, where both binding motifs are
on the same polypeptide chain. Simultaneous binding at equi-
molar concentrations is also consistent with the FP displace-
ment experiments of Figure 6, which show that the peptides
cannot displace each other at the starting concentrations of
the titration. For example, 30 nMFITC-NFAT-LxVP peptide could
not be displaced from 1.2 mM CnA up to 10 mM PRIEIT con-
centration, and similar effects are observed in complementary
titrations (Figure 6).
The fact that one peptide can displace the other at high
excess, while binding to a common, but not entirely identical,
epitope suggests the following model, which is visualized with
the cartoon of Figure 7A. One peptide alone adopts a bound
conformation that does not allow the other peptide to bind
without changing its conformation (I and III). Thus, high excess
of one peptide displaces the other. When both peptides are pre-
sent at equal concentrations, they adopt a different trimeric
conformation and do not dislocate each other (II). If one peptide
is in excess, the equilibrium shifts to the conformation that is
incompatible with the binding of the other peptide (transition
from II to I or III). The three states are visible in the NMR experi-
ment: the free NFAT-LxVP and NFAT-PxIxIT peptides are in Fig-
ures 4A and 5A; the dimeric complexes are in Figures 4B and 5B;
and the trimeric complexes are at the left-hand side of Figures
4C and 5C with either 15N-labeled LxVP or PxIxIT peptides. In
the trimeric complexes, unlike the bound conformation with
excess of each peptide, only parts of the peptides are tightly
bound to the Cn surface, which is clearly seen from the uneven
recovery of peptide signal intensities from dimeric to trimeric
complex transition. It should be noted that the trimeric condition
resembles the binding event of full-length NFAT with both motifs
on the same polypeptide chain, where concentrations of both
motifs are equal (IV).
It’s unlikely, yet possible, that the isolated NFAT-LxVP peptide
we used here may have different biophysical characteristics and
hence bind differently than do the intact NHR. The PxIxIT and the
LxVP segments might bind sequentially, so steric constraints
could direct the LxVP to another site once the PxIxIT segment
is already bound. To resolve this, cocomplex structures of Cn
with the full-length NHR or even entire NFAT would be needed.
The NMR-derived location of the LxVP binding site is depicted
in a surface representation of the CnAB heterodimer in Figure 7B.
Relevant to this study, a previous report indicated that an LxVP-
derived peptide inhibited dephosphorylation of the 19-residue
phosphopeptide substrate for Cn (the phosphopeptide RII,
DLPVPIPGRFDRRVpSVAAE), whereas the NFAT-PxIxIT peptide
did not show such an inhibitory effect (Martı´nez-Martı´nez et al.,
2006). This observation was used to support the notion that
the LxVP and PxIxIT motifs bind at different sites, and based
on docking studies, a putative LxVP binding epitope was pre-
dicted to reside at the CnA/B interface, overlapping with the
immunosuppressant binding site (Rodrı´guez et al., 2009) (Fig-
ure 7B). However, the binding mode presented here can fully
explain that earlier observation. The LxVP peptide directly com-
petes with binding of the RII peptide, which contains an LxVP
motif. This is not the case for the PxIxIT peptide, which can
bind simultaneously.016–1027, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 1023
Figure 7. LxVP and PxIxIT Peptides Bind to
an Overlapping Epitope on the CnAB Heter-
odimer
(A) Model for the conformational changes upon
Cn interaction with different concentrations of
LxVP- and PxIxIT-containing NFAT peptides. As
suggested by the experimental data, LxVP (I) or
PxIxIT (III) peptides alone form bound conforma-
tions incompatible with binding the other peptide.
Equimolar concentration of the binding peptides
leads to a trimeric bound structure of different
conformation (II). The trimetric condition resembles
the binding event of full-length NFAT, where both
motifs are on the same polypeptide chain (IV).
(B) Location of the NMR-derived LxVP binding site
on the surface representation of CnAB (Protein
Data Bank ID code 1AUI). The residues of the
NMR-derived LxVP and PxIxIT binding sites are
colored blue and red, respectively, with the over-
lapping site colored in magenta. The groove
connecting the LxVP binding site to Cn’s catalytic
center is shadowed in blue. The site in the CnA/B
interface suggested in a previous study (Ro-
drı´guez et al., 2009) is marked in orange.
(C) Model of NFAT regulatory domain in complex with CnAB depicting simultaneous PxIxIT and LxVP binding to an overlapping epitope. The lowest energy
model out of ten independent calculations using CYANA is shown (Herrmann et al., 2002). Phosphorylation sites are depicted with red spheres. The CnAB
structures are shown in the same color as in (B).
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NFAT’s PxIxIT and LxVP Bind Calcineurin JointlyIn another experiment, it was shown that mutating CnA resi-
dues 330–332 from NIR to AAA did alter calcineurin activity
toward the RII peptide as well (Li et al., 2004). This is now under-
standable because the Cn residues 330–332 are part of the
PxIxIT binding site and therefore also part of our NMR-derived
LxVP site. The fact that the RII peptide has an LxVP sequence
suggests that the triple mutation disrupts the LxVP interaction
at the overlapping epitope. The LxVP site within the RII peptide,
which lacks the neighboring WxK motif, could have a different
binding mode. But, in that case, the effects of the triple mutation
would be difficult to explain.
Our experiments reported here do not support the LxVP pep-
tide binding to a site between CnA and CnB subunits. The iden-
tification of the partially overlapping, but nonidentical, binding
sites for the two NFAT segments is compatible with the different
effects on dephosphorylation activity toward substrates. It
should also be noted that inhibition of Cn’s activity by the
LxVP sequence does not diminish the importance of this site
as a target for inhibiting NFAT dephosphorylation. Indeed, it
was shown more than a decade ago that both binding motifs,
PxIxIT and LxVP, need to be deleted to completely block NFAT
dephosphorylation by Cn, supporting the essential role each of
the sites plays in this interaction (Liu et al., 1999). Furthermore,
our experimental data place the LxVP site at a distance of
20 A˚ from calcineurin’s active center, which is closer than the
30 A˚ for the site predicted by the recent docking studies (Rodrı´-
guez et al., 2009). Considering the additional eight residues at
the C terminus of the LxVP peptide used in the recent docking
study, along with the physical proximity to the catalytic center
of the site we found experimentally, an explanation is provided
of how the LxVP peptide might be able to reach a site near
Cn’s active site and prevent access of the substrate peptide.
Indeed, in the representation of Figure 7B, a groove can be
seen connecting the LxVP site to Cn’s catalytic center capable1024 Structure 22, 1016–1027, July 8, 2014 ª2014 Elsevier Ltd All rigof accommodating the segment C-terminal to the LxVP motif
in the peptide.
The observation that the two NFAT segments bind Cn simulta-
neously and do not displace each other at equimolar concentra-
tions can readily explain earlier observations that addition of
a PxIxIT-containing peptide cannot fully prevent the nuclear
translocation process (Liu et al., 1999; Park et al., 2000). NFAT’s
regulatory domain can remain bound to the phosphatase by its
LxVP motif. Our findings show that the LxVP-derived peptide
binds to a site overlapped with the PxIxIT epitope, which re-
solves previous observations and establishes a distinct single
Cn epitope as the key target for inhibiting the Cn/NFAT
interaction.
The joint binding of the PxIxIT and LxVP motifs causes the
regulatory domain to form a loop that contains all phosphory-
lation sites (Figure 7C). This loop formation can constrain the
degrees of freedom of the bound NFAT regulatory domain and
could induce formation of a localized structural architecture
around the nuclear localization sequence and relate to the
mechanism controlling translocation. In addition, loop formation
of NFAT’s regulatory domain has the advantage of shortening
the distance of the phosphorylated residues to the active site
and is expected to facilitate the dephosphorylation reaction on
multiple sites (Figure 7B). Although the loop formation would
also be expected if the LxVP and PxIxIT sites bind distinct re-
gions on Cn, presence of the groove connecting the NMR-
derived PxIxIT/LxVP binding site to Cn’s catalytic center reveals
an advantage of loop formation by the partially overlapping
epitopes (Figure 7B).
TranslocationofNFAT to thenucleus isadecisiveevent forTcell
activation. It is triggered by calcium-induced activation of Cn
and subsequent dephosphorylation of NFAT’s regulatory domain.
Elucidating thedynamic interplayofNFAT’sCn-binding segments
provides crucial insight regarding the dephosphorylation processhts reserved
Structure
NFAT’s PxIxIT and LxVP Bind Calcineurin Jointlyand paves the way for understanding the nuclear translocation
mechanism and T cell activation. In addition, our study opens an
avenue for finding selective immunosuppressant drugs by relying
on the structural aspects of Cn-NFAT interactions. Indeed, we are
actively pursuing these questions via biophysical approaches in
subsequent studies.
EXPERIMENTAL PROCEDURES
Expression and Purification of CnA
The catalytic domain of human calcineurin A (CnA), which includes residues
2–347 with the substitutions of Y341S, L343A, and M347D (Aramburu et al.,
1998), was produced as a cleavable GB1 fusion protein containing a TEV
cleavage recognition site in the Escherichia coli strain BL21 (DE3). Cleavage
of the fusion protein with TEV protease produces CnA (2–347) with an addi-
tional Gly residue at its N terminus. CnA obtained is enzymatically active as
described earlier (Roehrl et al., 2004a). Expression of 2H,15N-labeled CnA
was obtained by growing E. coli in modified M9 Celtone medium, which con-
sists of 1 kg/l 99.8% D2O, 6 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl, 40 mg/l
carbenicillin, 1 g/l 15NH4Cl (99.9% enriched), 2 g/l
2H6-
13C6-glucose (97% en-
riched), 2mMMgSO4, 0.1 mMCaCl2, 10mg/l ZnSO4, 10mg/l FeCl3, and 0.5g/l
Celtone-based powder 2H (>97% enriched), 13C (>97% enriched), and 15N
(>98% enriched).
All expression experiments of labeled CnA were performed at 37C. After
reaching an optical density (OD; 600 nm) of 0.8, protein expression was
induced by the addition of 1 mM isopropyl b-D-1-thiogalactopyranoside)
(IPTG). The cells were harvested 36 hr after induction. The harvested cells
were resuspended in 40 ml of 50 mM Tris-HCl (pH 8.0), 300 mM NaCl and
30 mM imidazole, 5 mM b-mercaptoethanol (b-ME), and 0.5% glycerol. The
suspended cells were then disrupted by sonication, and the insoluble fraction
was removed by centrifugation for 20 min at 15,000 g. The supernatant was
applied to a 5 ml column of Nickel beads. After washing the resin with 40 ml
of 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 30 mM imidazole, 5 mM b-ME,
and 5% glycerol, the protein was eluted with PBS containing 5 mM b-ME
and 300 mM imidazole. The elution fraction was concentrated to 4 ml by using
10,000 MWC membrane ultrafiltration. TEV protease was added to the
concentrated elution fraction, and the solution was dialyzed with 1 l of PBS
with 10 mM imidazole. The digested solution was applied to the Ni-NTA
agarose column (QIAGEN) again and the flowthrough-containing CnA was
further purified over a Superedex75 column (GE healthcare). A typical final
yield of CnA was 2 mg/l culture.
Expression and Purification of Human Heterodimer CnAB
The plasmid for expressing the heterodimer calcineurin was obtained from
Addgene (ID 11787) and was expressed as a tandem expression system
as was previously described (Li et al., 2007; Mondragon et al., 1997). The
heterodimer CnAB protein complex was further purified using a Ni-NTA
agarose column (QIAGEN). After the His-tag was cleaved by overnight diges-
tion with thrombin at 4C, the protein solution was again passed through a
Ni-NTA column followed by a Superdex200 size-exclusion column (GE
healthcare).
Expression of the NFAT-LxVP, NFAT-PRIEIT, and PVIVIT-Containing
Peptides
The NFAT-LxVP peptide containing the sequence 384-DQYLAVPQHPYQWAK-
398 (NFATc1) was produced as a GB1 fusion protein in an E. coli strain, BL21
(DE3). The GB1 fusion protein has the PreScission protease recognition site
between GB1 and NFAT-LxVP peptide, which added a GP dipeptide at its
N terminus. For purification purposes, the construct was expressed with the
LEHHHHHH tag at its C terminus. For expression of the uniformly 2H15N13C-
labeled NFAT-LxVP peptide,E. coli harboring theGB1-NFAT-LxVP fusion vec-
tor was grown in M9 medium, which consists of 1 kg/l 99.8% D2O, 6 g/l
Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl, 50 mg/l Ampicilin, 1 g/l
15NH4Cl (99.9%
enriched), 2 g/l 2H6,
13C6-glucose (97% enriched), 2 mM MgSO4, and 0.1 mM
CaCl2. The cells were incubated at 37
C, and after reaching an OD (600 nm)
of 0.7, protein expression was induced by the addition of 1 mM IPTG overnight
in 25C. The cells were harvested and resuspended in 40ml of buffer A (50mMStructure 22, 1Tris-HCl [pH 8.0], 300 mMNaCl, and 20 mM imidazole) with 0.2 mg/ml phenyl-
methanesulfonylfluoride (PMSF) at 4C. The suspended cells were disrupted
by sonication, and the insoluble fraction was removed by centrifugation at
15,000 g for 20 min. The supernatant was applied to a 5 ml column of Ni-NTA
agarose. After washing the resin with 40 ml of buffer A, the GB1-NFAT-LxVP
peptide was eluted with 40 ml of buffer consisting of 50 mM Tris-HCl (pH
7.5), 300 mM NaCl, and 300 mM imidazole. The elution fraction was concen-
trated to 2 ml by 3000 MWC-membrane ultrafiltration. PreScission protease
and 1 mM DTT were added to the concentrated elution fraction. The digested
solutionwasdilutedwithbufferA to reduce imidazole concentration to less than
30 mM and passed through Ni-NTA column. The peptide was eluted with PBS
buffer at pH 3.4.
The NFAT-PRIEIT peptide contains the following NFATC2 sequence,
which was produced as a GB1 fusion protein in an E. coli strain, BL21(DE3):
WAAKPAGASGLSPRIEITPSHELIQAVGPLRM. The GB1 fusion protein has
the TEV recognition site between GB1 and NFAT-PRIEIT peptide. For purifica-
tion purposes, the construct was expressed with the LEHHHHHH tag at its
N terminus. For the expression of uniformly 2H15N13C-labeled NFAT-PRIEIT
peptide, E. coli harboring the correct plasmid was grown in M9medium, which
consists of 1 kg/l 99.8% D2O, 6 g/L Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl,
50 mg/l Ampicilin, 1 g/l 15NH4Cl (99.9% enriched), 2 g/l
2H6,
13C6-glucose
(97% enriched), 2 mM MgSO4, and 0.1 mM CaCl2. The cells were incubated
at 37C, and after reaching an OD (600 nm) of 0.7, protein expression was
induced by the addition of 1 mM IPTG overnight at 25C. The cells were har-
vested and resuspended in 40 ml of buffer A (50 mM Tris-HCl [pH 8.0],
300 mM NaCl, and 20 mM imidazole) with 0.2 mg/ml PMSF at 4C. The sus-
pended cells were disrupted by sonication, and the insoluble fraction was
removed by centrifugation at 15,000 g for 20min. The supernatant was applied
to a 5 ml column of Ni-NTA agarose. After washing the resin with 40 ml of
buffer A, the GB1-PxIxIT peptide was eluted with 40 ml of buffer consisting
of 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, and 300 mM imidazole. The elution
fraction was incubated with TEV in the presence of 1 mM DTT and 0.5 mM
EDTA overnight to allow for cleavage. The digested solution was diluted with
buffer A (without Imidazole) to reduce imidazole concentration to less than
30 mM and passes through the Ni-NTA column. The flowthrough containing
the peptide was collected followed by Superdex75 size-exclusion column
chromatography.
The peptide containing the 15-residue PVIVIT sequence and His tag
(GPHPVIVITGPHEELEHHHHHH) was expressed with similar procedures as
described previously (Takeuchi et al., 2007).
NMR Spectroscopy
All experiments were performed on either Bruker Avance 500, 600, 750, or 800
MHz spectrometers equipped with cryogenic probes. All spectra were
collected using 30 mM sodium phosphate buffer (pH 6.8) containing
150 mM NaCl, 1 mM dithiothreitol (DTT; in the experiments containing MTSL
no DTT was used), and 90%H2O/10% D2O at 298 K. Spectra were processed
using nmrPipe (Delaglio et al., 1995) and analyzed with SPARKY (Goddard and
Kneller, 2008). The partial backbone assignment of CnA and the backbone
assignment of the LxVP and PxIxIT peptides were accomplished using stan-
dard TROSY triple-resonance experiments as described previously (Takeuchi
et al., 2007).
Fluorescence Polarization Assay
Fluorescence measurements were made on samples arrayed in 384-well
plates by using an EnVision Multilabel Reader to monitor the interaction
between Cn and FITC-labeled peptides. All measurements were done in
triplicate. Experimental polarization data from simple and competitive
binding experiments were fitted using GraphPad Prism6, with error bars rep-
resenting SD.
Spin Labeling of a Single Cysteine Residue
A five molar excess of the MTSL spin label [(1-oxyl-2,2,5,5-tetramethylpyrro-
line-3-methyl)-methanesulfonothioate] was incubated with a Q385C mutant
of the GB1-NFAT-LxVP protein sample for 4 hr at room temperature. Excess
spin label was removed by size-exclusion chromatography using Superdex75
column. Further purification was done in a similar way to the LxVP peptide to
remove GB1 and purify the resulting LxVP peptide.016–1027, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 1025
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All chemicals were purchased from Sigma unless otherwise noted. Celtone
powder was purchased from Spectra Stable Isotopes. MTSL for spin labeling
was purchased from Toronto Research Chemicals.
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